Please assess the completion status of the following clinical trial:

Trial Title: Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed NSCLC in stage IIIB (with a cytologically positive pleural or pericardial effusion) or stage IV, according to the sixth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual37;~* Age \> 18 years;~* No prior chemotherapy, including adjuvant or neoadjuvant therapy, for the treatment of NSCLC;~* Histological confirmation of any non-squamous histological type of NSCLC, given the recent findings of treatment benefit in this population44;~* ECOG performance status of 2;~* At least 3 weeks must have elapsed since major surgery, and at least 1 week since mediastinoscopy, pleuroscopy, or thoracostomy;~* Patients must have measurable disease, defined as lesions that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques (computed tomography \[CT\] or magnetic resonance imaging \[MRI\] scan) or as ≥ 10 mm with spiral CT scan;~* Adequate organ function as indicated by the following:~  * White blood cell (WBC) count ≥ 3500/mm3~ * Absolute neutrophil count (ANC) ≥1500/mm3~ * Hemoglobin ≥ 9.0 g/dL~ * Platelet count ≥ 100,000/ mm3~ * Total bilirubin ≤ 2 times the upper limit of normal (ULN)~ * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the ULN, unless liver metastases present, in which case AST and ALT have to be ≤ 5 times the ULN~ * Estimated glomerular filtration rate (GFR) ≥ 45 mL/min~* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration;~* Fertile patients (male or female) must agree to use an acceptable method of contraception to avoid pregnancy for the duration of the study and for 3 months thereafter;~* Patients must sign an Informed Consent Form;~* Have the ability to take folic acid, Vitamin B12, and dexamethasone according to protocol requirements;~Exclusion Criteria:~* ECOG performance status other than 2;~* Prior chemotherapy for the treatment of NSCLC;~* Lesions that have been irradiated cannot be included as sites of measurable disease. If the only measurable lesion was previously irradiated the patient cannot be included;~* Symptomatic central nervous system (CNS) metastases. Prior CNS metastases are allowed if the patient is neurologically stable and not receiving corticosteroids;~* Serious uncontrolled intercurrent medical or psychiatric illness;~* Active and ongoing systemic infection;~* Second primary malignancy (except in situ carcinoma of the cervix, in situ carcinoma of the bladder, adequately treated basal-cell carcinoma of the skin, adequately treated squamous-cell carcinoma of the skin, T1 vocal cord cancer in remission, or prior malignancy treated more than 5 years prior to enrollment and without recurrence);~* Known hypersensitivity to pemetrexed;~* known hypersensitivity to carboplatin;~* Pregnancy or lactation;~* Use of any investigational agent within 30 days prior to enrollment into the study;~* Unable to discontinue administration of non-steroidal anti-inflammatory (NSAIDSs) agents for 2 days before, the day of and 2 days after the dose of pemetrexed, in the case of NSAIDs with short half-life, such as ibuprofen (total of 5 days), in patients with a GFR between 45 and 79 mL/min; and for 5 days before, the day of and 2 days after the dose of pemetrexed, in the case of NSAIDs with long half-life (total of 8 days, see 7.4.2) in all patients; patients with a GFR ≥ 80 mL/min may receive concomitant study treatment and ibuprofen or aspirin (≤ 1.3 g/day);~* Inability to comply with requirements and procedures of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm B (Type: EXPERIMENTAL): Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\] + Antiemetic therapy at investigator's discretion.
- Arm A: (Type: ACTIVE_COMPARATOR): Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).